Market News

Sartorius is offering its expertise to enhance scientific education and practice.

Company achieves the £9 million calendar year royalty cap on net sales of Ellipta products a year earlier than previously guided.

Expands softgel development and manufacturing capabilities and capacity.

The proposed biosimilar to Neulasta is used to reduce the duration of neutropenia and the incidence of fever associated with neutropenia in adult patients treated with chemotherapy in certain types of cancer.

Investment in a inductively coupled plasma mass spectrometry system is a move to address the updated ICH Q3D regulatory guidelines on elemental impurities.

Trends include ‘human factor’ principles, with ‘individualised packaging and serialisation’ as the integral solutions of the future.

Generic Pharmaceutical Association becomes Association for Accessible Medicines.

Complidermol 5α PLUS tackles not only the known hormonal factor, but also the oxidative and inflammatory factors, new pathophysiological factors identified as causes of this condition.

Acquisition paves the way for Quotient to replicate its Translational Pharmaceutics platform in America.

Symbiosis Pharma now able to offer East and West Coast clients small-scale aseptic manufacturing capabilities to support clinical trials.

Easyhaler is a dry powder inhaler for the treatment of asthma and COPD.

The Expanding role of pharmacovigilance in rapidly changing regulatory and commercial climates.

Foresee technology can help to develop stable, formulated peptides in solution for controlled-release therapy for 3- and 6-month durations of action after a single injection.

Favourable macro trends will be reflected at CPHI South East Asia where domestic manufacturers are increasingly attending the event, with a view to opening up sales in international markets.

The initial US$1.3 million order is to supply components for ultra low temperature robotic storage systems in the US to major pharmaceutical companies.

PharmaCote ECxtra has been developed to stop the issues encountered by hard chrome, but still provide a coating that provides excellent tooling protection.

Praluent continues to be available to patients in the US.

Partnership to explore and identify new tools and methods to modify and optimize the CHO cell line performance.

IDT expands its capacity for direct sales of genomic products in Asia-Pacific region.

GSK launches Flonase Sensimist allergy relief nationwide.

Trulicity is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist injectable prescription medicine.

Company to introduce its portfolio of generics in France.

Vial injector, pharma compliance pack, smart packaging and autoinjector for prefilled syringes named best innovations in 2017.

The partnership will integrate Genedata Screener software with TTP Labtech’s acumen Cellista and mirrorball to improve screening data management.

Personal medical device leveraging "Internet of Things" technologies to address medication adherence.

By the end of 2017, company plans to increase to 230 process chemists and 70 analytical chemists.

Acquisition of Extrakt Chemie and site investments in people, equipment, manufacturing buildings and new offices increases company's position in Germany.

The growing number of states and countries getting approval for using marijuana in therapeutic applications is a crucial factor driving the demand over the coming few years.

A team of industry experts reward Nemera’s autoinjector with a Pharmapack Award as best innovation product.

Opdivo has now been approved in six tumour types in just over 2 years.

The company’s growth has been driven by export, with a three-fold increase in activity outside of the UK during 2016,

Rentschler will become the first and only CDMO to have access to Leukocare's patented SPS formulation technologies.

Acquisition provides fully equipped facilities for the development and manufacture of clinical stage cellular therapy products, including three ISO7 cGMP manufacturing suites, extensive flow cytometry and analytical infrastructure.

The Dublin offices are the company's first permanent business premises outside of North America.

Patent found to be invalid.

Acquisition creates world-class aesthetic and regenerative medicine business in plastic surgery.

Bioverativ common stock to be traded on the NASDAQ global select market.

Xyzal is an oral antihistamine with a proven 24-hour effect.

Patents in question invalidated based on obviousness.

The enlarged business will comprise 21 manufacturing centres and commercial operations across 60 countries.

Manufacturing projects in eco-friendly and biodegradable packaging, which is expected to surge in near future.

New perfeXion system, which generates around 100,000 data tags/min, makes an important contribution to quality assurance for downstream post-processing steps at the beginning of the value chain.

Developments in local manufacturing, regulatory strategies, market entry and harmonisation to be debated by MENA leaders and Government.

Effectively handles difficult-to-mix pharmaceutical ingredients.

First treatment approved in 5 years for adolescents aged 13-17 years with schizophrenia.

Actelion R&D unit to spin out into standalone company based and listed in Switzerland.

Issued claims are directed to a series of orally available small molecules and their use in treating epilepsy, neuropathic pain, and other neurological disorders.

New dosage strength expected to be available in first quarter of 2017.

Company expects to invest cost savings in its branded and generics business segments.

Clinical trial is the first of its kind to treat IBS symptoms by cannabinoid-containing chewing gum.

Disease prevalence can be monitored with a precision never before possible.

GenVec's AdenoVerse to be integrated into Intrexon's proprietary synthetic biology platform.

Investments include an LC-MS/MS, and GC-MS with head-space capability, for improved and rapid identification of trace unknown extractable compounds.

Site enlargement enables increased capacity for state-of-the-art quality control and storage.

Feasibility study to examine three different oral formulations engineered with Enteris’ Peptelligence platform.

Extends multi-year agreement in drug discovery with focus on cardiovascular and central nervous system disorders, immunology, infectious diseases and oncology.

The first chemically-defined, animal component-free, cell culture medium for T cells.

No admission of wrongdoing, No monetary payment by Endo.

Merck to pay BMS and Ono royalties on global sales of Keytruda through 2026, and lump-sum payment of $625 million.

Cold-EEZE will become Mylan's largest US OTC brand franchise.

Deal will enhance Lilly's existing pain management portfolio for migraine and adds potential near-term launch to its late-stage pipeline.

Company's subsidiary currently involved in patent litigation concerning this product.

Regulatory compliant, FDA-audited facility based in Mollet des Vallès, Spain.

The settlement and license agreement will strengthen Biogen's IP for leading oral therapy for multiple sclerosis.

Suliqua will be delivered in two pre-filled SoloSTAR pens, providing different dosing options that may help answer individual market and patient insulin needs.

leon nanodrugs' MJR technology offers reformulation options that address API solubility issues.

WHF therapy can be directly applied on a wound to stimulate the natural human wound healing process.

Transaction includes US commercialization rights for Onivyde for metastatic pancreatic cancer in adult patients.

No concerns raised by FDA related to the rolapitant IV efficacy or safety profile and additional clinical studies are not required.

Novo Nordisk to launch Fiasp in first half of 2017.

Product receives designations for both the BV treatment and prevention indications.

Comprehensive validation services for the Chinese market.

All programs (two promising clinical-stage programs targeting DNA damage and repair, and two novel pre-clinical programs) have first-in-class and best-in-class potential.

If the patent is ultimately upheld through all remaining challenges, Alimta would maintain US exclusivity until May 2022.

New study to evaluate combination of Lartruvo and Keytruda.

Company aims to increase production capacity to supply multiple commercial-scale therapeutic vaccines under development.

Collaboration will give Pierre Fabre the option to enter into exclusive negotiations to license global rights for the program in selected skin cancer conditions.

Expansionincludes the opening of two new process development centers in the US and China.

Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities.

Scientists can confirm, in one easy step, whether an antibody has been successfully conjugated.

Generis is the most sold pharmaceutical brand in Portugal, and is the #2 generic group in Portugal.

Deal expands Allergan's innovative GI [ipeline with ABI-M201 and ABI-M301, preclinical compounds targeting Uucerative colitis and Crohn's disease, as well as future compounds for irritable bowel syndrome.

KumaMax could provide hope celiac patients who try, but are unable to completely avoid gluten exposure in their diets,

JOTROL is being developed to remedy resveratrol’s poor bioavailability and dose limiting gastrointestinal side effects.

Company collaborating with all participants in the pharma supply chain to tackle to the epidemic of prescription drug abuse.

Ariad stockholders to receive $24.00 per share in cash.

A ready-to-use, stable and soluble, parenteral form of clopidogrel is feasible using the company's nanoemulsion platform technology.

Christi Shaw hired to lead Bio-Medicines; Conterno to assume additional geographic responsibilities, including Lilly USA leadership; Zulueta to lead International business.

Phase Ib/II studies to explore a novel immuno-oncology combination in hematological and solid tumours with high unmet medical need.

Noxxon continues transition to clinical oncology company.

PolyPeptide Laboratories' acquisition brings immediate access to additional large-scale capacity in synthesis, purification and isolation of peptides.

Concordia will continue to be responsible for the manufacturing and supply of Donnatal in all territories.

Appointment of Ian Clark as Non-Executive Director.

Website allows visitors to simply and quickly locate pertinent information.

Presentation provides new data regarding the mechanism of the ControLyo Technology.

Each company will separately pursue their own vaccine strategies in Europe.

Investigation reveals improper expense reimbursements.

Agreement includes the commercialization and development rights to the newly approved EU drug Zavicefta (ceftazidime-avibactam).

Computationally intelligent drug discovery platform receives two Fierce Innovation awards for Biotech Innovation and Best New Product.

Development and licence agreement is for pMDI inhaled triple therapy (VR2076) for asthma and COPD.

Oral Otezla receives positive NICE recommendation for adults with psoriatic arthritis.

Mr Wilkinson no longer President and CEO and a member of the Board.

Acquisition adds global portfolio of sterile injectables, robust pipeline, and manufacturing capabilities.

Novartis and Sunovion Pharmaceuticals strike agreement for three COPD treatments.

Caforio will succeed Lamberto Andreotti effective 2 May 2017.

Key products include Alloderm and Stratticem tissue matrices commonly used in breast reconstruction and abdominal wall surgeries.

The agreement also provides an option to have Lonza exclusively supply API for up to 20 years.

Acquisition of Encore Vision, to add first-in-class disease modifying topical treatment for presbyopia patients to the Novartis ophthalmology pipeline in an area of high unmet medical need and high prevalence

Agreement is the first step in TPI Enterprises’ plan to expand its presence in the UK market.

Labeling revisions also include updates to corresponding warning and addition of clinical data on superior efficacy of Chantix compared with bupropion or nicotine patch.

Pharmapack 2017: focus on tailor-made packaging. solutions

Guidelines include new recommendation to consider the use of Jardiance in people with type 2 diabetes and established cardiovascular disease to reduce the risk of cardiovascular death.

Authorized generic offered at more than 50% below wholesale acquisition cost of EpiPen auto-injector.

In its decision, the jury also concluded that Gilead “willfully” infringed upon the patent.

apceth Biopharma will perform clinical manufacturing, process validation activities and commercial manufacturing for LentiGlobin and Lenti-D drug product.

Acquisition will make Lonza a fully integrated solutions provider in oral delivery technologies and active ingredients to the consumer healthcare and nutrition markets.

Catalent Biologics will employ its proprietary GPEx cell line technology and ambr workstation to develop, optimize the process for expression, and manufacture antibodies for further investigation by MVI and its partners.

Laboratory and office facility to be constructed on the site by 2019.

Several late-stage pipeline drugs are expected to achieve blockbuster status by the end of 2022,